1887

oa Current Allergy & Clinical Immunology - Pimecrolimus cream 1% in atopic dermatitis : a 6-month, open-label trial in paediatric patients - : product news

Volume 23, Issue 3
  • ISSN : 1609-3607

 

Abstract

Pimecrolimus, a new, non-steroid, inflammatory-cytokine inhibitor, has been shown to prevent progression to flare in atopic dermatitis (AD) and to improve long-term disease control when applied as a 1% cream. In this 6-month, open-label, multinational study, 177 infants aged 3-23 months and 489 children aged 2-17 years, with mild to severe AD, were included. The study was designed to evaluate the efficacy and safety of pimecrolimus cream 1% used as a first-line treatment.

Loading full text...

Full text loading...

Loading

Article metrics loading...

/content/caci/23/3/EJC21659
2010-08-01
2019-08-22

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error